Bangalore-based Kemwell Biopharma has announced the acquisition of US-based Cirrus Pharmaceuticals, which specialises in contract development services.
Cirrus is a highly reputed contract product development organisation. Cirrus has been serving the needs of the global pharmaceutical industry for over 15 years. Since its inception in 1997, Cirrus has established a strong reputation for its development expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms.
It also offers stand-alone analytical services including stability studies.
Kemwell chairman and MD Anurag Bagaria said: "Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company. Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development.
"Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell’s EMA, FDA and PMDA approved facilities in India and Sweden."
Dr Ninad Deshpanday, president of R&D at Kemwell, said: "With Cirrus’ development capabilities and Kemwell’s manufacturing expertise, we will be able to develop products with faster time-to-clinic and significant cost savings for our customers."
Cirrus’ president Dr Anthony Hickey added: "This acquisition is a testament to the tremendous value our talented employees have created for Cirrus over the past several years.
"The acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms.
"The Cirrus team looks forward to joining the Kemwell family and continuing to provide the high customer satisfaction it always has."